Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Session VI: Biomarkers and Novel Clinical Parameters in Immunotherapeutic Clinical Trials

Potential biomarkers of immune activation in ipilimumab-treated patients with advanced melanoma

David Berman
David Berman
Bristol-Myers Squibb, Princeton, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2008
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Ipilimumab is a fully human, monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 (CTLA-4) − a key negative regulator of T-cell responses to tumor-associated antigens.

Ipilimumab treatment results in durable disease control in patients with advanced melanoma. The most common adverse events are mechanism-based (immune-related adverse events [irAEs]) and primarily affect the gastrointestinal (GI) system. In a randomized, double-blind, placebo-controlled, multicenter, phase II study (CA184-007), patients with unresectable stage III or IV melanoma received ipilimumab induction dosing 10 mg/kg every 3 weeks (Q3W) X 4 + placebo/prophylactic budesonide, an oral steroid with minimal systemic exposure hypothesized to reduce GI irAEs. Objectives of the biomarker analyses were to assess the effect of ipilimumab on peripheral T-cell populations during the induction phase (i.e., to Week 12) and to evaluate potential biomarkers of irAEs, particularly GI. Absolute lymphocyte count (ALC) captured in study CA184-007 was combined with data from 2 other phase II studies of advanced melanoma patients who received ipilimumab 10 mg/kg Q3W X 4 (CA184-008 and CA184-022). Response was assessed by modified World Health Organization (mWHO) criteria; the first efficacy assessment was at Week 12. Flow cytometric analysis on pre- and post-treatment blood and serum samples from 115 treated patients (CA184-007) showed that ipilimumab increased the frequency of activated CD4+ and CD8+ T cells during the first 4 weeks of treatment (96% increase each) which was maintained to Week 12 (an additional 33% and 57% increase, respectively). Ipilimumab decreased naïve T cells by Week 12 (91% and 81% decrease for CD4+ and CD8+ T cells, respectively). There was a small, overall mean increase in the frequency of central memory CD4+ and CD8+ T cells from baseline at Weeks 4 and 12, but no meaningful changes in effector memory T cells. In the multi-study analysis (n = 329), responding patients had higher ALC levels, and no patient with an ALC decrease over the induction period responded; these results were highly statistically significant (P = 6 x 10-4). These results suggest that ipilimumab activates the immune system, and that ALC may predict response to treatment. No predictive biomarkers of irAEs were identified.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

  • Copyright © 2008 by David Berman
PreviousNext
Back to top
Cancer Immunity Archive: 8 (Suppl 2)
January 2008
Volume 8, Issue Suppl 2
  • Table of Contents

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Potential biomarkers of immune activation in ipilimumab-treated patients with advanced melanoma
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Potential biomarkers of immune activation in ipilimumab-treated patients with advanced melanoma
David Berman
Cancer Immun January 1 2008 (8) (Suppl 2) 22;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Potential biomarkers of immune activation in ipilimumab-treated patients with advanced melanoma
David Berman
Cancer Immun January 1 2008 (8) (Suppl 2) 22;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Identification of antibody responses induced in patients with biochemically recurrent and castration-resistant prostate cancer receiving GVAX immunotherapy for prostate cancer
  • Clinical response to the MAGE-A3 immunotherapeutic in metastatic melanoma patients is associated with a specific gene profile present prior to treatment
  • Harmonized T cell monitoring assays as biomarkers for immunotherapy trials: A data driven approach by the CIMT Immunoguiding Program ("CIP")
Show more Session VI: Biomarkers and Novel Clinical Parameters in Immunotherapeutic Clinical Trials
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement